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Abstract
The two major barriers militating against rapid containment of the spread of coronavirus (CoV) disease (COVID)-19 
include lack of effective contact tracing and the failure to detect and diagnose the infection early. Lack of diagnostic 
tools for early diagnosis has contributed to the bane of the current wild spread of COVID-19 and its containment. The 
current chest computed tomography (CT) for COVID-19 screening, an evolving technique, is arguably reported to 
have 97% diagnostic sensitivity over the viral polymerase chain reaction (PCR) that has detection of 70%. However, 
CT has largely been criticized as speculative and thus generates disagreement among various international radiology 
societies and organizations. Until now, nucleic acid detection by real-time PCR (advanced with next-generation 
sequencing) remains the gold standard test and clinical diagnosis technique for COVID-19. The use of this method 
in diagnoses, while it is more precise, is also time-consuming and may not meet the goal of rapid detection of early 
infection with severe acute respiratory syndrome CoV-2. Although many available tests, such as other PCR-based, 
serology, isothermal nucleic amplification, and among others, are coming up, the testing accuracy and/or timeliness 
have hampered their expected performance level. As a result, there is still a need to develop more methods to 
detect the current spread of COVID-19 rapidly. COVID-19 is now associated with olfactory dysfunctions in several 
reports. Recently, the Centers for Disease Control (CDC) established that anosmia is a notable symptom of COVID-
19. Furthermore, acute systemic acidosis has been associated with COVID-19. This report critically discusses the 
potential pathophysiologies of COVID-19 in association with neuropathological and acid-base disorders and their 
prospect for diagnostics.
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Highlights of the Study
•	 Detection of early cases of COVID-19 remains a 
big concern against the containment operation
•	 This report discusses the pathophysiology of 
a neuropathological disorder, anosmia, as a 
possible diagnostic tool
•	 It also discusses the pathophysiology and 
potential diagnostic use of an associated acid-
base disorder in COVID-19 patients
•	 The report concludes that putting apparatus, 
such as respiratory or smelling testing panels, 
into use could add to the benefit of early 
detection operation.
Introduction
The two major barriers militating against 
rapid containment of the spread of coronavirus (CoV) 
disease 2019 (COVID-19) include lack of effective 
contact tracing and the failure to detect and diagnose 
the infection early. Lack of adequate diagnostic tools for 
early diagnosis has impacted the current wild spread 
of COVID-19 and its containment. Extensive studies 
are ongoing to address these problems, especially for 
asymptomatic and presymptomatic patients. Majority of 
COVID-19 cases (81%) show mild or no symptoms [1]. 
Unfortunately, these individuals may shed the virus and 
fuel the contagion. It becomes a matter of urgency to 
develop and improve on rapid diagnostic tools to aid 
early detection of severe acute respiratory syndrome 
CoV 2 (SARS-CoV-2) infected individuals, who are 
oftentimes asymptomatic before they can spread the 
disease. It is believed that asymptomatic spread has 
been aggravating the pandemic control of COVID-19.
In search of rapid techniques for detection of 
early infection with SARS-CoV-2, the chest computed 
tomography (CT) for COVID-19 screening has been found 
to detect 97% of COVID-19 cases and rapidly within 10 
mins, while viral polymerase chain reaction only detects 
70% sensitivity [2]. However, 97% sensitivity report with 
CT screening has been largely criticized as speculative 
and shows a lack of consensus among various reputable 
societies such as the American College of Radiology, 
Royal College of Radiologists, Royal Australian and New 
Zealand College of Radiology, and Canadian Association 
of Radiologists [2]. Recently, millions of antibody test kits 
ordered by UK governments in the wake of an urgent 
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call to detect asymptomatic and presymptomatic patients 
and to prevent the rapid transmission of COVID-19 were 
not consistent and, thus, unreliable. Likewise, millions 
of test kits purchased by Slovakia, Czech Republic, and 
Spain from China were largely inaccurate [3].
Meanwhile, COVID-19 draws myriads of signs 
and symptoms with related pathogeneses. Of recent, 
the CDC established six more symptoms to the list of 
COVID-19 symptoms, including anosmia [4]. Up till date, 
the report has been associating anosmia/hyposmia, 
a neuropathological disorder with COVID-19 [5], the 
pathogenesis of which has not been clearly identified. 
Although an earlier study conducted retrospectively in 
Italy through a self-report identification method shows 
a low incidence rate of 19.4% [6]. In general, incidence 
rates of olfactory dysfunction (OD) in COVID-19 patients 
ranging between 33.9% and 68% [7] from further studies 
showed increased discovery rates. In other words, as 
time evolved with more research studies intensified 
toward containment of COVID-19, various investigations 
involving larger sample sizes, and/or more robust 
techniques show continued to show higher prevalence 
rates with the cases of OD becoming more evident and 
gradually taken into clinical considerations [8-11]. Of 
note is a multicenter-study that later reported an 85.6% 
prevalence rate with larger coverage, including many 
European countries such as Belgium, France, Spain, 
and Italy using questionnaire method [8]. Remarkably, a 
study conducted in Iran with the aid of a validated method 
using a 40-odorant test (University of Pennsylvania 
Smell Identification Test, method) reported about 98% 
smell dysfunctions proposing that ODs would serve as 
a key indicator to identify SARS-CoV-2-infected patients 
[10]. In addition, apart from OD, the respiratory disorder 
is generally associated with ventilation problems and a 
possible etiology of acute and chronic systemic acidosis in 
some pulmonary affected diseases. This report discusses 
the pathophysiologies of neuropathological and acid-
base disorders in relation to olfactory dysfunction and 
systemic acidosis and their prospect in the diagnoses of 
COVID-19 and population surveillance.
Emerging Neuropathological Disorder in 
COVID-19 and its Diagnostic Prospect
Report from the experts in rhinology shows that, 
currently, there are large numbers of patients who tested for 
COVID-19 infection and developed anosmia/hyposmia in 
South Korea, China, Germany, Iran, US, France, and Italy 
[5]. The report further explains that majority of these patients 
present with anosmia even without other symptoms [5]. 
Recently, the CDC enlisted six more to the tally of COVID-
19 symptoms [4]. It is believed that certain forms of OD 
may be impacted in anosmia/hyposmia. Post-viral olfactory 
disorder has been described as one of the possibilities in 
developing anosmia [12]. The exact mechanism of olfactory 
neurobiology behind the development of post-viral anosmia 
in COVID-19 has not been reported. Nonetheless, two 
possible etiologies may be associated with the apparent 
loss of smell. The first probable etiology could be related to 
loss of maintenance or replacement of olfactory neuron as 
a result of post-viral damage in relation to the reduction of 
basal stem cell in the olfactory neuroepithelium. Another but 
different mechanistic plausibility is immunobiological which 
may be related to constant inflammatory post-viral damage 
that may have impaired either or both olfactory neuron 
and basal cell function. In a related study, early data show 
that provoked inflammatory reactions (implicating some 
inflammatory cytokines, such as interleukins-6 and 1β) 
occur in both upper and lower respiratory tracts following 
infection with SARS-CoV-2 with consequent respiratory 
problems ranging from mild to extensive life-threatening 
lung injury [13].
While in search of simple and sensitive detection 
diagnostic or screening tools, the development of smell 
testing kits and/or symptom diagnostic criteria may offer 
significant testing opportunities in this area of COVID-19 
pathology. In clear terms, the development of symptom 
diagnostics may involve identifying vital differentials that will 
clearly indicate loss of smell, specifically in relation to post-
viral infection with SARS-CoV-2, following the exclusion 
of unrelated pathological disorders that may range from 
chronic rhinitis to neurodegenerative processes. In 
addition to testing diagnostic kits, the development of 
OD symptom diagnostic criteria may add values to early 
detection of COVID-19 in combination with the existing 
diagnostic techniques for various OD manifestations. It is 
believed that the use of simple odorant testing kits and 
symptom diagnostic criteria could reduce the time spent 
on laboratory diagnoses and possibly aid in early detection 
or screening process during containment operations.
COVID-19 with an Associated Acid-base 
Disorder and the Diagnostic Utility
Apart from asymptomatic cases, several 
individuals with mild symptoms or presymptomatic may 
also escape quarantine control measure and continue 
to spread the virus through several contacts. It may be 
essential to develop screening panels or diagnostics in 
relation to change in body physiology. The successful 
development of screening panel and rapid diagnostic tools 
required for the detection of COVID-19 suspected cases 
have been hampered due to complex mechanisms of 
pathogenesis of the disease that underlie the development 
of signs and symptoms. Besides, signs and symptoms in 
patients suffering from COVID-19 are diverse in range and 
this also contributes against the development of effective 
rapid diagnostics. Pathophysiologically, the development 
of signs and symptoms is generally a result of alteration 
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in body physiology. In other words, the development 
of signs and symptoms has clinical correlations with 
changes in body function. Alteration in body chemistry 
could also serve an advantage to develop screening or 
detection panel to support early diagnosis.
Cases of COVID-19 have been reported with 
the involvement of multiple organs. Likewise, SARS-
CoV-2 has been detected in blood, feces, and urine 
samples [14]. It is not certain whether SARS-CoV-2 
is transported through a lymphohematogenous route 
to other organs similar to other agents of pulmonary 
infection that has been reported elsewhere in distal 
body tissues [15]. However, the common signs and 
symptoms in COVID-19 are particularly related to 
respiratory problems. Clinical manifestations relating 
to respiratory symptoms such as cough, dyspnea 
(shortness of breath), runny nose, and other secondary 
effects of a respiratory problem involving tachycardia, 
hypoxia, acidosis, and among other findings have been 
reported [14], [16]. Respiratory acidosis is a complication 
of breathing problem. In the buildup of body acidosis, 
there is a reduction in arterial body pH and stimulation 
of peripheral chemoreceptors that result in increased 
ventilatory drive under body regulation through a 
compensatory mechanism. As described in Figure 1, the 
presence of an obstructive gas exchange body tends 
to increase more CO2 in the body in consequence of 
alveolar hypoventilation that drives respiratory acidosis 
due to the creation of an acidic environment. Alveolar 
hypoventilation leads to an increased PaCO2. Ventilatory 
defect that leads to the acid-base disorder may offer 
useful diagnostic information in identifying suspected 
cases of COVID-19. Estimation of changes in arterial 
pCo2/pO2 can be done through a breathing record of 
inspired and expired gasses using various respiratory 
gas measurements and thus stands a rapid advantage 
to pave new screening or diagnostic opportunities.
Figure 1: Development of acute respiratory distress in critical cases 
associated with COVID-19
Conclusion
Knowledge of the changes in body physiology 
and/or chemistry from the available clinical information 
in relation to the pathophysiologies of associated 
neuropathological and acid-base disorders in COVID-
19 may help in better understanding the disease and 
also aid the development of screening or diagnostic 
tests. Perhaps, this may circumvent waiting long for 
laboratory analyses or development of biomarkers or 
add to the diagnostic efficiency of COVID-19. Thus, 
the development of respiratory virus testing panels 
that are highly sensitive and specific for SARS-CoV-2 
target may help in containment operation through the 
detection of the hidden carriers who are asymptomatic 
or presymptomatic.
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